Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REPRISE EDGE 29 mm EU Study: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE 29 mm Valve - Evaluation of Safety and Performance

NCT02964962 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT02964962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02964962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REPRISE EDGE 29 mm EU Study: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE 29 mm Valve - Evaluation of Safety and Performance
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Withdrawn
Start date
April 1, 2018
Completion date
December 30, 2018
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aortic valve stenosis